Hepatitis C News

Patients with chronic hepatitis C virus infection are at a higher risk of being diagnosed with around 70% of the diseases captured by the ICD-10, according to a presentation at the International Liver Congress in Paris.

PARIS — Direct-acting antiviral therapy effectively treated hepatitis C virus in patients with high MELD scores, producing a high rate of sustained viroloic response, according to a presentation at the International Liver Congress 2018.

The incidence of lymphoma — Hodgkin and non-Hodgkin — was up to 15 times higher among patents with HIV monoinfection and HIV/hepatitis C virus coinfection compared with the general population, according to findings presented at the International Liver Congress in Paris.

PARIS — In patients with hepatitis C virus genotype 4, 8 weeks of Zepatier showed effective treatment of the virus, according to a presentation at the International Liver Congress 2018.

PARIS — Although sustained virologic response maintained a high level no matter the alcohol or cannabis consumption in a German registry, those who reported drinking alcohol in excess were more likely to be lost to follow-up, according to a presentation at the International Liver Congress 2018.

PARIS — Though some direct-acting antivirals conflict with the administration of hormone replacement therapy or oral contraceptives, a recent study showed safety and efficacy with Zepatier, according to a our exclusive interview with Christophe Hezode, MD, at the International Liver Congress 2018.

PARIS — Researchers evaluated the cost-effectiveness of regular hepatocellular carcinoma screening among patients with hepatitis C after sustained virologic response. In this exclusive video from the International Liver Congress 2018, Hooman Farhang Zangneh, MD, MSc, discusses the thresholds and limitations for cost-effective liver cancer screening.

PARIS — Using a new medication and generic sofosbuvir, researchers reached 97% sustained virologic response in patients with hepatitis C both with and without cirrhosis; in this exclusive video from the International Liver Congress 2018, Drugs for Neglected Diseases Initiative (DNDi) addresses the impact of this research.

PARIS — Two real-world studies presented at the International Liver Congress 2018 confirmed the efficacy and safety of Mavyret in Italy and Germany even in the face of multiple comorbidities.

PARIS — Treating hepatitis C virus in the early stage of disease saves money in drug and medical costs while lowering risk for decompensated cirrhosis, hepatocellular carcinoma, liver transplant and liver-related death, according to a presentation at the International Liver Congress 2018.